Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Generation of murine tumor models refractory to αPD-1/-L1 therapies due to defects in antigen processing/presentation or IFNγ signaling using CRISPR/Cas9

PLoS ONE(2024)10.1371/journal.pone.0287733Source: DataRank Database

Generation of murine tumor models refractory to αPD-1/-L1 therapies due to defects in antigen processing/presentation or IFNγ signaling using CRISPR/Cas9 is a research paper published in PLoS ONE (2024). On theSindex it has a DataRank of 0. It has been cited 2 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access2 citations

Download PDF

Cite:

Linked data & code

cellosaurus

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 0.48)OA: goldTopics (37)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (7)

Christine M. Minnar ORCID,Mayank Tandon ORCID,Mary R. Guest ORCID,Raj Chari ORCID,Jeffrey Schlom ORCID

Live enrichment

PubMed:38427670 PMC:PMC10906908 OpenAlex:https://openalex.org/W4392388579

Department of Health and Human Services and funds from the NCI, NIH

Grant: HHSN261201500003I

NCI NIH HHS

Grant: HHSN261201500003C

National Institutes of Health

Intramural Research Program of the Center for Cancer Research, National Cancer Institute

FWCI

0.48

Citation Percentile

0.6%

Citation Trend

2025

2026

goldLicense: cc-by

journalhttps://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0287733&type=printable

publisherhttps://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0287733&type=printable

publisherhttps://dx.plos.org/10.1371/journal.pone.0287733

journalhttps://doi.org/10.1371/journal.pone.0287733

repositoryhttps://pubmed.ncbi.nlm.nih.gov/38427670

Fields of Study

CRISPR and Genetic EngineeringCAR-T cell therapy researchCancer Immunotherapy and BiomarkersAnimalsMiceAntigen PresentationB7-H1 AntigenCell Line, TumorCRISPR-Cas SystemsProgrammed Cell Death 1 ReceptorRNA, Guide, CRISPR-Cas SystemsSignal Transduction

MeSH Terms

RNA, Guide, CRISPR-Cas SystemsAnimalsHumansSignal TransductionAntigen PresentationCell Line, TumorMiceB7-H1 AntigenProgrammed Cell Death 1 ReceptorCRISPR-Cas Systems

Keywords

CRISPRCancer researchPD-L1Immune checkpointImmune systemBiologySanger sequencingCancerAntigen presentationImmunotherapyT cellMutationImmunologyGeneGenetics

Sustainable Development Goals

SDG 0: Good health and well-being

Generation of murine tumor models refractory to αPD-1/-L1 therapies due to defects in antigen processing/presentation or IFNγ signaling using CRISPR/Cas9

FAIR Checklist

Authors (7)

Funding (4 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)